Education
About Us
Working with TipRanks
Follow Us
Matthew Gall Insider Profile
4 Followers
Matthew Gall, CFO at iTeos Therapeutics, holds 0.00 shares in iTeos Therapeutics (Ticker: ITOS), holds ― shares in Kalaris Therapeutics (Ticker: KLRS).
Profitable Transactions
3 out of 3 Profitable Transactions
Average Return
+53.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Matthew Gall does not currently own shares as a corporate insider.
A breakdown of Matthew Gall's holdings
Insider Roles
Chief Financial Officer
Roles that Matthew Gall holds in companies
Most Profitable Insider Trade
Stock:
iTeos Therapeutics
(ITOS)
(ITOS)
Rating:Informative Buy
Date:Jun 16, 2021 - Jun 16, 2022
Return:+83.80%
The most profitable trade made by Matthew Gall
Matthew Gall's Trading History
iTeos Therapeutics
Aug 29, 2025
―
Uninformative Sell
―
$0.00
Kalaris Therapeutics
―
Chief Financial Officer
―
―
List of latest transactions for each holding click on a transaction to see Matthew Gall's performance on stock
You May Also Like
Matthew Gall insider profile FAQ
What is the percentage of profitable transactions made by Matthew Gall?
The percentage of profitable transactions made by Matthew Gall is 100%.
What is the average return per transaction made by Matthew Gall?
The average return per transaction made by Matthew Gall is 53.30%.
What stocks does Matthew Gall hold?
Matthew Gall holds: ITOS, KLRS stocks.
What was Matthew Gall’s latest transaction?
Matthew Gall latest transaction was an Uninformative Sell of ―.
What was Matthew Gall's most profitable transaction?
Matthew Gall’s most profitable transaction was an Informative Buy of ITOS stock on June 16, 2021. The return on the trade was 83.80%.
What is Matthew Gall's role in iTeos Therapeutics?
Matthew Gall's role in iTeos Therapeutics is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.